Clinical Trials
10
Active:4
Completed:5
Trial Phases
4 Phases
Phase 1:2
Phase 2:2
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Not Applicable
2 (28.6%)Phase 1
2 (28.6%)Phase 2
2 (28.6%)Phase 3
1 (14.3%)Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Phase 3
Recruiting
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
- Interventions
- Genetic: Ixo-vec
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Adverum Biotechnologies, Inc.
- Target Recruit Count
- 284
- Registration Number
- NCT06856577
- Locations
- 🇺🇸
Adverum Clinical Site 223, Gilbert, Arizona, United States
🇺🇸Adverum Clinical Site 178, Phoenix, Arizona, United States
🇺🇸Adverum Clinical Site 126, Phoenix, Arizona, United States
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
Active, not recruiting
- Conditions
- Diabetic Macular EdemaDiabetic Retinopathy
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Adverum Biotechnologies, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT05607810
- Locations
- 🇵🇷
Adverum Clinical Site, Arecibo, Puerto Rico
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Phase 2
Active, not recruiting
- Conditions
- Neovascular Age-related Macular Degeneration
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Adverum Biotechnologies, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT05536973
- Locations
- 🇺🇸
Adverum Clinical Site 178, Phoenix, Arizona, United States
🇺🇸Adverum Clinical Site 126, Phoenix, Arizona, United States
🇺🇸Adverum Clinical Site 159, Tucson, Arizona, United States
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
Active, not recruiting
- Conditions
- Wet Age-related Macular DegenerationNeovascular Age-related Macular Degeneration
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Adverum Biotechnologies, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04645212
- Locations
- 🇺🇸
Adverum Clinical Site, The Woodlands, Texas, United States
ADVM-022 Intravitreal Gene Therapy for DME
Phase 2
Completed
- Conditions
- Diabetic Macular EdemaDiabetic Retinopathy
- Interventions
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Adverum Biotechnologies, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04418427
- Locations
- 🇵🇷
Adverum Clinical Site, Arecibo, Puerto Rico
- Prev
- 1
- 2
- Next
News
No news found